• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

18.47 -0.87 (-4.50%)
Delayed Quote Updated: 10:36 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,641
Open 19.08
Bid (Size) 18.19 (100)
Ask (Size) 18.68 (1,000)
Prev. Close 19.34
Today's Range 18.25 - 20.55
52wk Range 5.550 - 29.27
Shares Outstanding 25,676,798
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
November 02, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
October 26, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire

Performance

52-Week Range 36.9% below 52-week high
18.47
5.5552W Low 29.2752W High
1 Week 6.9% below 1-week high
17.911W Low 19.831W High

Nuvectis Pharma, Inc. - Common Stock (NVCT) traded between $5.55 and $29.27 over the past 52 weeks and last traded at $18.47, 36.9% below its 52-week high. Over the past week it ranged between $17.91 and $19.83.

Past 12 Months
+0.6%
-13.7%
-8.1%
+90.2%
+117.0%
+190.4%
1W +$0.11
1M -$2.92
3M -$1.63
6M +$8.76
YTD +$9.96
1Y +$12.11

NVCT was +190.4% over the past year, +90.2% over six months, +117.0% year to date, +0.6% in the last week.

12 Months vs Market
NVCT
+190.4%
DIA
+11.9%
SPY
+12.0%
QQQ
+10.2%
IWM
+15.0%

Over the past 12 months NVCT returned +190.4% versus DIA (Dow) +11.9%, SPY (S&P 500) +12.0%, QQQ (Nasdaq 100) +10.2% and IWM (Russell 2000) +15.0%.

Volume & Liquidity 0.10× 3-mo avg
Today 20,641 3-mo avg 198.8K
1W
167.2K
1M
171.1K
3M
198.8K
6M
248.1K
YTD
173.4K
1Y
159.9K

NVCT most recently traded 20,641 shares against a 3-month average daily volume of 198.8K.

More News

Read More
News headline image
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
October 09, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
September 24, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma To Participate in Upcoming Investor Conferences
September 03, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Nuvectis Pharma, Inc. (NASDAQ: NVCT) Prices $100 Million Public Offering
July 15, 2026
Via Investor Brand Network
News headline image
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
July 14, 2026
Via Newsfile
Here are the top movers in Tuesday's session. ↗
June 30, 2026
Via Chartmill
Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗
June 30, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
June 30, 2026
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
June 30, 2026
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
June 29, 2026
Via Chartmill
News headline image
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
June 29, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
June 24, 2026
Via Chartmill
Here are the top movers in Wednesday's session. ↗
June 24, 2026
Via Chartmill
News headline image
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
June 22, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 14, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
March 31, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
December 17, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
November 25, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
November 04, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 27, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Nuvectis Pharma, Inc. - Common Stock publicly traded?
Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.
What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?
Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?
The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market
What is the current price of Nuvectis Pharma, Inc. - Common Stock?
The current price of Nuvectis Pharma, Inc. - Common Stock is 18.47
When was Nuvectis Pharma, Inc. - Common Stock last traded?
The last trade of Nuvectis Pharma, Inc. - Common Stock was at 11/04/26 10:36 AM ET
What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?
The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 474.25M
How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?
Nuvectis Pharma, Inc. - Common Stock has 474M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap